Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

VIMSELTINIB for Soft tissue neoplasm: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 64 adverse event reports in the FDA FAERS database where VIMSELTINIB was used for Soft tissue neoplasm.

Most Reported Side Effects for VIMSELTINIB

Side Effect Reports % Deaths Hosp.
Fatigue 57 33.5% 0 0
Pruritus 23 13.5% 0 0
Swelling face 23 13.5% 0 0
Peripheral swelling 22 12.9% 0 0
Nausea 20 11.8% 0 0
Headache 17 10.0% 0 1
Periorbital swelling 17 10.0% 0 0
Eye swelling 16 9.4% 0 0
Rash 15 8.8% 0 0
Arthralgia 13 7.7% 0 0
Product dose omission issue 12 7.1% 0 1
Blood creatine phosphokinase increased 11 6.5% 0 0
Pain 11 6.5% 0 0
Periorbital oedema 9 5.3% 0 0
Product use issue 9 5.3% 0 0

Other Indications for VIMSELTINIB

Giant cell tumour of tendon sheath (86) Connective tissue neoplasm (67) Product used for unknown indication (10) Synovitis (9)

Other Drugs Used for Soft tissue neoplasm

PEXIDARTINIB (223) PAZOPANIB (85) NIROGACESTAT (40) IMATINIB (24) NIVOLUMAB (20) CABOZANTINIB S-MALATE (17) SORAFENIB (14) SUNITINIB MALATE (14) CABOZANTINIB (12) IFOSFAMIDE (11)

Related Pages

VIMSELTINIB Full Profile All Soft tissue neoplasm Drugs VIMSELTINIB Demographics VIMSELTINIB Timeline